Methods and compositions for enhancing the viability of microneedle pores
AssigneeF6 Pharma, Inc.
InventorsAudra Lynn Stinchcomb, Stan Lee Banks
Life of this patent
Estimating the term…
Abstract
Described herein is a method of transdermally administering one or more pharmaceutically active agents to a mammal. The method comprises administering one or more active pharmaceutical agents to the skin of the subject, in conjunction with microneedles and one or more COX inhibitors, whereby the COX inhibitors facilitate the absorption of the active pharmaceutical agents by prolonging the pore opening created by the application of the microneedle.
Claims31
A transdermal drug delivery system comprising:
- a. a first array of microneedles;
- b. a first COX inhibitor comprising diclofenac or a salt thereof, and
- c. an active pharmaceutical agent;
- wherein the first COX inhibitor is different from the active pharmaceutical agent.
(canceled)
(canceled)
(canceled)
9-16. (canceled)
A method for transdermally administering an active pharmaceutical agent comprising the steps of:
- a. contacting the skin with a first array of microneedles;
- and
- b. applying a composition comprising:
- (i) a first COX inhibitor comprising diclofenac or a salt thereof, and
- (ii) an active pharmaceutical agent to be transdermally delivered,
- wherein the first COX inhibitor is different from the active pharmaceutical agent.
(canceled)
(canceled)
(canceled)
26-32. (canceled)
A method of prolonging microneedle pore viability comprising the steps of:
- a. contacting the skin with a first array of microneedles;
- and
- b. applying a composition comprising an active pharmaceutical agent to be transdermally delivered and a first COX inhibitor comprising diclofenac or a salt thereof;
- wherein the first COX inhibitor is different from the active pharmaceutical agent.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.